Catalent Bolsters Drug Development Capabilities
Catalent Pharma Solutions has unveiled plans to invest $5 million in the creation of a new drug development center of excellence (CoE) at its Somerset, NJ facility and headquarters. The investment will see the site focus on preclinical to clinical phase 2b formulation, analytical, and manufacturing solutions for orally delivered small molecules. It will also build upon the site's expertise in the development of modified release formulation, bioavailability solutions, the application of OptiMelt hot melt extrusion (HME) technology, and its status as the company's CoE for handling potent compounds and controlled substances.
"This latest investment in Somerset will significantly strengthen our early development offering with focused formulation expertise and capacity for additional speed and flexibility," said Jonathan Arnold, president of Catalent's oral drug delivery business unit. "It is highly complementary to Catalent's West Coast facility in San Diego, CA and further positions Catalent as the strategic partner of choice for the early development of solid oral dose forms."
Catalent's 265,000 square-foot headquarters and development center in Somerset has a long track record of successfully developing, launching, and manufacturing many oral treatments for leading global innovators. The site features state-of-the-art analytical labs, pilot and clinical scale equipment including HME and fluid bed processing, and significant expertise in coating technologies, capsules, tablets, minitablets, and multi-particulates.
Catalent's early phase drug development sites are closely connected to Catalent's clinical supply services network, to optimize transition from finished dose manufacture to clinical packaging and distribution. In addition, the Somerset facility will offer seamless transfers to Catalent's integrated commercial manufacturing network in: Kansas City, MO; Winchester, KY; Swindon, UK; and Schorndorf, Germany, for later stage clinical trials using compatible, scalable equipment.
2026-10-11
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
India Proposes New GMP Rules for Clinical Trial and API Manufacturing
-
CPHI & PMEC India 2026
-
8th Annual Pharma Manufacturing and Automation Convention 2026
-
Pharma Manufacturing & Automation Excellence Awards 2026
-
CPHI Korea 2026: A Leading Gateway to Korea’s Pharmaceutical and Biopharma Market
-
Pharmaconex
-
Pharma Quality Excellence Awards 2026 - Celebration and Conclusion
-
Pharma Quality Reimagined: Highlights from the 6th Annual Pharma GMP & Quality Management 2026
-
From Feedmill to Food System: VIV Europe 2026 Addresses the Industry's Most Critical Challenges
-
Beyond Compliance: Building Quality Maturity
Recommend Reading
-
Henkel to Acquire Olaplex in $1.4 Billion Deal
-
Due to Supply Chain Disruptions, A Major MDI/TDI Facility in the Middle East has Suddenly Shut Down!
-
350 Million Yuan! Shandong Huayang Dr Chemical Industry Co., Ltd.'s Nitric Acid Expansion in Ningyang, Tai'an
-
IMCD Acquires Dong Yang FT, Entering the Korean Beauty Sector
-
Nouryon Doubles Triethylaluminum Co-catalyst Capacity in China and Makes Several Major Investments
-
Business Society’s Market Outlook for Hydrofluoric Acid on August 31, 2026: Price Trend Is Volatile
-
This week, the caustic soda price was weak (10.27-10.30) in China
-
Adequate Supply, PP Market Weak in Mid-November in China
-
Business Society’s Market Outlook for Maleic Anhydride on August 31, 2026: Volatile
-
Business Society’s August 12, 2026 Acrylic Acid Market Outlook: Clearly Upward Trend
- Hot Searches
- chlorfenapyr insecticide
- ethyl acetate distributor
- where to get sulfur hexafluoride
- zirconia fused alumina
- nonanoic acid
- tirzepatide research peptide for sale
- nacl safety data sheet
- methylamine price
- high density polyethylene price
- dipotassium phosphate for food market
- meg pricing
- clind ph benzoyl perox